Traditional knowledge: Protecting age-old practices

The Chinese have sworn by it for generations. India is known for lauding its healing powers. In tribal regions of sub-Saharan Africa it’s a viable alternative to over-the-counter pharmaceuticals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Novo Nordisk ramps up semaglutide defence as generics lurk

9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.

Asia

Novo Nordisk India strategy suffers semaglutide patent setback

4 December 2025 The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.

Asia

WIPR Rankings reveals the go-to firms and attorneys for China patent work

7 November 2025 Sister title WIPR’s China Patent Rankings detail the firms and individuals most capable of handling patent matters in the country, from litigators with winning streaks to global strategists.

More features

From Edwards to Insulet: Three key medical device cases of 2025

5 ways the USPTO director is changing US innovation

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

Novo Nordisk ramps up semaglutide defence as generics lurk

Novo Nordisk India strategy suffers semaglutide patent setback

Traditional knowledge: Protecting age-old practices

More on this story

Editor's picks

Editor's picks

More features